1
|
López IH, Parada D, Gallardo P, Gascón M, Besora A, Peña K, Riu F, Arquez Pianetta M, Abuchaibe O, Torres Royò L, Arenas M. Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy. Rep Pract Oncol Radiother 2017; 22:251-257. [PMID: 28479874 DOI: 10.1016/j.rpor.2017.02.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2016] [Revised: 01/09/2017] [Accepted: 02/25/2017] [Indexed: 11/29/2022] Open
Abstract
OBJECTIVES Ki-67 is a proliferation marker in prostate cancer. A prognostic RNA signature was developed to characterize prostate cancer aggressiveness. The aim was to evaluate prognostic correlation of CCP and Ki-67 with biochemical failure (BF), and survival in high-risk prostate cancer patients (pts) treated with radiation therapy (RT). METHODS CCP score and Ki-67 were derived retrospectively from pre-treatment paraffin-embedded prostate cancer tissue of 33 men diagnosed from 2002 to 2006. CCP score was calculated as an average expression of 31 CCP genes. Ki-67 was determined by IHC. Single pathologist evaluated all tissues. Factors associated to failure and survival were analyzed. RESULTS Median CCP score was 0.9 (-0-1 - 2.6). CCP 0: 1 pt; CCP 1: 19 pts; CCP 2: 13 pts. Median Ki-67 was 8.9. Ki-67 cutpoint was 15.08%. BF and DSM were observed in 21% and 9%. Ki-67 ≥ 15% predicted BF (p = 0.043). With a median follow-up of 8.4 years, 10-year BF, OS, DM and DSM for CCP 1 vs. CCP 2 was 76-71% (p = 0.83), 83-73% (p = 0.86), 89-85% (p = 0.84), and 94-78% (p = 0.66). On univariate, high Ki-67 was correlated with BF (p = 0.013), OS (p = 0.023), DM (p = 0.007), and DSM (p = 0.01). On Cox MVA, high Ki-67 had a BF trend (p = 0.063). High CCP score was not correlated with DSM. CONCLUSIONS High Ki-67 significantly predicted outcome and provided prognostic information. CCP score may improve accuracy stratification. We did not provide prognostic correlation of CCP and DSM. It should be validated in a larger cohort of pts.
Collapse
Key Words
- ADT, androgen deprivation therapy
- Biomarkers
- CCP genes
- CCP, cell cycle progression
- CSS, cause-specific survival
- CTCv3.0, common terminology criteria for adverse events
- CTV, clinical target volume
- DFS, disease-free survival
- DMFS, distant metastasis free survival
- FFbF, freedom from biochemical failure
- GI, gastrointestinal
- GU, genitourinary
- Gy, gray
- HE, hematoxylin and eosin
- IHC, immunohistochemical
- Ki-67
- OS, overall survival
- PCa, prostate cancer
- PSA, prostate specific antigen
- Prostate cancer
- RT, radiation therapy
- pts, patients
Collapse
Affiliation(s)
- Iván Henríquez López
- Radiation Oncology Department, University Hospital of Sant Joan, Institute d'Investigació Sanitaria Pere Virgili (IISPV), Reus, Tarragona, Spain
| | - David Parada
- Pathology Department, University Hospital of Sant Joan, Institute d'Investigació Sanitaria Pere Virgili (IISPV), Reus, Tarragona, Spain
| | - Pablo Gallardo
- Faculty of Medicine, University Hospital of Sant Joan, Reus, Tarragona, Spain
| | - Marina Gascón
- Radiation Oncology Department, University Hospital of Sant Joan, Institute d'Investigació Sanitaria Pere Virgili (IISPV), Reus, Tarragona, Spain
| | - Arnau Besora
- Bioinformatics, Institute d'Investigació Sanitaria Pere Virgili (IISPV), Reus, Tarragona, Spain
| | - Karla Peña
- Pathology Department, University Hospital of Sant Joan, Institute d'Investigació Sanitaria Pere Virgili (IISPV), Reus, Tarragona, Spain
| | - Francesc Riu
- Pathology Department, University Hospital of Sant Joan, Institute d'Investigació Sanitaria Pere Virgili (IISPV), Reus, Tarragona, Spain
| | - Miquel Arquez Pianetta
- Radiation Oncology Department, University Hospital of Sant Joan, Institute d'Investigació Sanitaria Pere Virgili (IISPV), Reus, Tarragona, Spain
| | - Oscar Abuchaibe
- Department of Radiation Oncology, Virgilio Galvis Ramirez Cancer Centre, Bucaramanga, Colombia
| | - Laura Torres Royò
- Radiation Oncology Department, University Hospital of Sant Joan, Institute d'Investigació Sanitaria Pere Virgili (IISPV), Reus, Tarragona, Spain
| | - Meritxell Arenas
- Radiation Oncology Department, University Hospital of Sant Joan, Institute d'Investigació Sanitaria Pere Virgili (IISPV), Reus, Tarragona, Spain
| |
Collapse
|